



FOR IMMEDIATE RELEASE

IMMUNOTEC ANNOUNCES AGREEMENT

VAUDREUIL-DORION, QC, November 4, 2013 – Immunotec Inc. (TSX VENTURE EXCHANGE: IMM), a Canadian based company and a leader in the wellness industry (the “Company”) and Mr. Robert Henry, its former Chairman and Chief Executive Officer, are pleased to announce that they have amicably concluded a final settlement to their mutual satisfaction with respect to the claims regarding Mr. Henry’s past involvement with the Company, for a total amount payable to Mr. Henry of USD\$522,000.

The Company thanks Mr. Henry for his contribution to the Company. Mr. Henry also expresses his appreciation to the Company’s founders, the management team and the Company’s employees, distributors and customers.

About Immunotec Inc.

Immunotec Inc. is dedicated to making a positive difference in people’s health and lifestyle every day by offering research-driven nutritional products through its network of Independent Consultants worldwide. Immunotec’s products are led by the flagship brand, Immunocal. Immunocal is a unique, specially-formulated natural protein product that has been clinically demonstrated and patented to optimize your immune system. Immunotec’s strength comes from its culture that emphasizes teamwork and entrepreneurial leadership by employees, consultants and research collaborators.

Headquartered with manufacturing facilities near Montreal, Canada, Immunotec Consultants generate nearly \$50 Million in annual revenue. Please visit us at www.immunotec.com for additional information.

The Company files its consolidated financial statements, its management and discussion analysis report, its press releases and such other required documents on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Patrick Montpetit CPA; CA CF, Vice President and Chief Financial Officer, Immunotec Inc. (450) 510-4527.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Immunotec’s most recent Management’s Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.